Persistent reflux, swallowing difficulty, regurgitation, or chest discomfort may require more than symptom-based treatment. A structured esophageal evaluation can help determine whether symptoms are caused by GERD, Barrett’s esophagus, a motility disorder, altered anatomy, or another condition.
Barrett’s esophagus is a change in the lining of the lower esophagus in which normal squamous lining is replaced by intestinal-type columnar lining. It is associated with chronic gastroesophageal reflux disease and increases the risk of developing esophageal adenocarcinoma.
Barrett’s esophagus is not cancer.
Most patients with Barrett’s esophagus do not develop esophageal cancer. The purpose of appropriate surveillance is to identify precancerous changes, called dysplasia, or early cancer at a stage when endoscopic treatment can be highly effective.
Barrett’s esophagus is more common in people with chronic GERD and certain additional risk factors. Screening is not recommended for everyone with heartburn.
Current gastroenterology guidance supports considering a screening upper endoscopy in selected patients with chronic GERD who also have multiple additional risk factors, such as older age, male sex, White race, tobacco use, obesity, or a family history of Barrett’s esophagus or esophageal adenocarcinoma.
Screening decisions should be individualized rather than based on a website checklist alone.
Barrett’s esophagus is diagnosed with upper endoscopy and biopsy. During endoscopy, the physician examines the esophageal lining and obtains tissue samples when appropriate. The pathology report determines whether intestinal metaplasia is present and whether there is dysplasia.
If dysplasia is reported, expert pathology review is often important because grading dysplasia can be challenging and directly affects treatment.
Most patients diagnosed with Barrett’s esophagus do not have dysplasia. Management commonly includes reflux treatment and periodic endoscopic surveillance.
Surveillance intervals depend on the length of the Barrett’s segment, pathology, prior findings, and current guidelines. Rather than publishing a rigid schedule that may become outdated, the website should emphasize individualized surveillance based on current recommendations.
Dysplasia means that cells within Barrett’s tissue have developed precancerous abnormalities. It may be classified as indefinite for dysplasia, low-grade dysplasia, or high-grade dysplasia.
Confirmed dysplasia changes the management discussion. Current guidelines support endoscopic eradication therapy for high-grade dysplasia and generally favor it for appropriately confirmed low-grade dysplasia, while selected patients with low-grade dysplasia may choose close surveillance after a detailed discussion of risks and benefits.
Endoscopic treatment can remove or destroy abnormal Barrett’s tissue without traditional esophageal surgery. Treatment may include endoscopic resection of visible abnormalities followed by ablation of remaining Barrett’s tissue when appropriate.
Visible lesions should be evaluated carefully.
When Barrett’s contains a visible abnormality, endoscopic resection can provide both treatment and more accurate tissue staging before additional ablation is considered.
EGD allows direct examination of the esophagus, gastroesophageal junction, and stomach. It can identify esophagitis, Barrett’s esophagus, narrowing, hiatal hernia, ulcers, masses, and other structural abnormalities. Biopsies can be obtained when indicated.
Ambulatory reflux monitoring measures acid exposure in the esophagus over time. Testing may use a wireless pH capsule or a catheter-based pH or pH-impedance system.
The test can help confirm or exclude pathologic reflux, especially when endoscopy does not already establish the diagnosis or when an antireflux procedure is being considered. Depending on the clinical question, testing may be performed off or on acid-suppressing medication.
High-resolution manometry measures pressure and muscle coordination as the esophagus moves food toward the stomach. It is particularly useful for evaluating difficulty swallowing and for identifying major motility disorders.
Manometry is also important before many antireflux procedures because conditions such as achalasia can mimic reflux symptoms and may require a very different treatment.
A barium swallow provides a dynamic X-ray view of swallowing and upper gastrointestinal anatomy. It can be useful for evaluating hiatal hernia, narrowing, altered anatomy, esophageal emptying, or postoperative anatomy. It complements rather than replaces endoscopy, reflux testing, or manometry.
Not every patient with regurgitation, chest discomfort, or swallowing difficulty has GERD. Motility disorders affect how the esophagus contracts and how the lower esophageal sphincter relaxes.
High-resolution manometry is central to diagnosing major esophageal motility disorders. Treatment depends on the specific diagnosis rather than simply increasing reflux medication.
An operation can correct reflux anatomy, but it cannot fix the wrong diagnosis. Objective testing helps confirm GERD, define hiatal hernia anatomy, identify Barrett’s or esophagitis, and make sure the esophagus can move food appropriately.
Symptoms can overlap.
GERD, achalasia, functional heartburn, reflux hypersensitivity, hiatal hernia, and other disorders can produce overlapping symptoms. The purpose of testing is to identify the mechanism before choosing treatment.
Obesity is associated with GERD and is also an important risk factor in the Barrett’s esophagus discussion. For patients who have both obesity and significant reflux, treatment planning may involve both foregut and metabolic considerations.
When bariatric surgery is being considered in a patient with significant GERD or Barrett’s esophagus, the choice of operation matters. Roux-en-Y gastric bypass is often an important option because of its favorable effect on reflux, while sleeve gastrectomy can worsen reflux in some patients.
New or severe chest pain should not automatically be assumed to come from the esophagus. Cardiac and other urgent causes may need to be excluded.
No. Barrett’s increases the risk of esophageal adenocarcinoma, but most patients with Barrett’s do not develop cancer. Surveillance is designed to detect important changes early.
Endoscopic eradication therapy can eliminate visible Barrett’s tissue and intestinal metaplasia in appropriately selected patients with dysplasia or early neoplasia, but ongoing surveillance remains necessary because recurrence can occur.
Not necessarily. Surveillance intervals depend on Barrett’s length, pathology, prior findings, and current guidelines.
pH testing measures reflux exposure. Manometry measures esophageal pressure and movement. They answer different questions.
A normal endoscopy does not exclude GERD. Reflux monitoring can provide objective evidence when the diagnosis remains uncertain.
Manometry involves passing a thin catheter through the nose into the esophagus. It can be uncomfortable, but the study is typically brief and provides information that cannot be obtained from endoscopy alone.
Antireflux treatment can control reflux, but surgery should not be presented as eliminating the need for Barrett’s surveillance. Patients with Barrett’s should continue guideline-directed follow-up.
This requires individualized bariatric and foregut evaluation. Significant GERD or Barrett’s can influence procedure selection, and Roux-en-Y gastric bypass may be favored in selected patients.
The purpose of foregut testing is not to order every test for every patient. It is to choose the right test for the clinical question, establish the diagnosis, and then select treatment based on evidence, anatomy, physiology, and patient goals.
This page is for general educational purposes and does not replace individualized medical advice. Screening, surveillance intervals, biopsy protocols, diagnostic testing, and treatment depend on patient-specific findings and current clinical guidelines.
This draft is intended to align with current American College of Gastroenterology guidance on Barrett’s esophagus and GERD, American Society for Gastrointestinal Endoscopy guidance on GERD and Barrett’s esophagus, and current standards for physiologic esophageal testing. Screening criteria, surveillance intervals, dysplasia management, and endoscopic therapy recommendations should be verified before publication and reviewed periodically.
